Hence, exposure of cancer and endothelial cells to 0.5-1μM concentrations of tasquinimod will produce intracellular levels of 2 to 3 μM or more than twenty-fold higher than needed to bind and thus also inhibit HDAC4 and S100A9 [12, 18]. The gene discussed is S100A9; the disease is cancer.